Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles matching "Leukemia, Myeloid, Acute"

Clinical trialUNITERAREMay 5

New Recruiting Trial: Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Novartis is testing a drug called asciminib in children who have a type of blood cancer called chronic myeloid leukemia (CML) that has a specific genetic change called the Philadelphia chromosome. This is a Phase 2 trial, which means researchers are checking if the drug works well and is safe in this younger age group. The study is now accepting patients and is expected to start in May 2026.

WHY IT MATTERSThis trial is the first to test asciminib specifically in pediatric patients with Ph+ CML-CP, potentially offering a new treatment option for children who may have limited alternatives or resistance to current therapies.
→ You can act on thisChronic Myeloid Leukemia, Chronic PhasePhiladelphia chromosome-positive CML
Clinical trialUNITERAREMay 3

New Recruiting Trial: Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Researchers are testing a new combination of three drugs—bugitinib, venetoclax, and cytarabine—to treat acute myeloid leukemia (AML) that has come back or stopped responding to previous treatment. This is an early-stage study (Phase 2) that is now accepting patients. The goal is to see if this drug combination works better than current options for this serious blood cancer.

WHY IT MATTERSThis trial offers a new treatment option for patients with relapsed or refractory AML, a condition with limited effective therapies, and is actively recruiting participants now.
→ You can act on thisacute myeloid leukemiarelapsed acute myeloid leukemiarefractory acute myeloid leukemia
Clinical trialUNITERAREApr 3

New Recruiting Trial: A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Researchers are testing a new drug called elritercept to see if it works better than a standard treatment (epoetin alfa) for anemia in adults with myelodysplastic syndromes (MDS)—a blood disorder where the bone marrow doesn't make enough healthy blood cells. People in this study have low, very low, or intermediate risk MDS and need regular blood transfusions. The trial is now accepting patients.

WHY IT MATTERSThis Phase 3 trial is actively recruiting adults with MDS who require transfusions, offering access to an investigational treatment that may reduce their dependence on blood transfusions.
→ You can act on thisMyelodysplastic Syndromes

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases